• CD38 CAR Binder Structures and Affinity Tuning

  2026-08-22

  Cheng and colleagues dissect how the CD38-targeting CAR binders RP02 and 028 recognize distinct structural regions and differentially affect CD38 enzymatic activity. The study further shows that rational attenuation of the 028 binder can reduce CAR-T fratricide while preserving antitumor cytotoxicity, providing a structure-guided framework for balancing potency and selectivity.

• LBP Protects Muscle Through AMPK-Linked Mitophagy

  2026-08-22

  The 2025 reference study identifies an AMPK/PINK1/Parkin-mediated mitophagy pathway through which Lycium barbarum polysaccharide (LBP) alleviates high-fat-diet-associated skeletal muscle atrophy and metabolic dysfunction. Its use of pathway inhibition and Parkin knockdown strengthens the interpretation that mitochondrial quality control is mechanistically important, although translation beyond experimental sarcopenic obesity models remains to be established.

• Viral RIPK3 Degradation and Necroptotic Inflammation

  2026-08-21

  Liu et al. identified a viral inducer of RIPK3 degradation (vIRD) that hijacks host SCF ubiquitin-ligase machinery to suppress necroptosis during orthopoxvirus infection. The study connects vIRD-dependent loss of RIPK3 with viral replication, inflammation, mortality, and pathogen–host evolution, providing a mechanistic framework for studying virus-regulated protein degradation.

• Meropenem Workflows for Resistance Research

  2026-08-20

  Meropenem supports reproducible susceptibility testing, time-kill analysis, and Gram-negative infection models built around a defined PBP-directed mechanism. This guide distinguishes practical assay starting points from evidence-based comparisons and shows how to troubleshoot degradation, inoculum effects, and resistance-associated variability.

• Oleic Acid (C18:1(9Z)) Experimental Workflow

  2026-08-20

  Build reproducible lipid-loading, signaling, and hepatocyte injury assays with Oleic Acid rather than treating fatty-acid exposure as a one-variable experiment. This guide translates the OAPA liver model into practical preparation, controls, readouts, troubleshooting, and cross-model decision points.

• Trichostatin A: From Histone Marks to Cell-Cycle Control

  2026-08-19

  Trichostatin A (TSA) is more than a broad HDAC inhibitor: it is a useful perturbation tool for connecting histone acetylation with cell-cycle, differentiation, and centrosome phenotypes. This article explains how to design more causally informative cancer research assays around TSA.

• Thapsigargin: From Calcium Pulse to ER Stress

  2026-08-19

  Thapsigargin is a SERCA pump inhibitor that converts calcium-store manipulation into a precisely timed experimental signal. This guide explains how to distinguish acute calcium dynamics from downstream endoplasmic reticulum stress and how the reference study informs stronger assay design.

• Cefotaxime: From Resistance Genes to Assays

  2026-08-18

  Cefotaxime can do more than generate a susceptibility endpoint: it can help connect beta-lactam antibiotic mechanism, resistance genotype, and transfer potential. This article presents a decision-focused assay framework grounded in recent CREC transmission research.

• Dimetridazole: Designing Antivirulence Assays

  2026-08-18

  Dimetridazole, also known as 1,2-Dimethyl-5-nitroimidazole, is best evaluated through assays that distinguish quorum sensing disruption from direct growth inhibition. This guide presents an evidence-based workflow for biofilm, combination, transcriptomic, and infection model research.

• AmpC/AmpD Resistance to Ceftolozane-Tazobactam

  2026-08-17

  Deroche and colleagues combined isogenic Pseudomonas aeruginosa mutants, sequential time-kill experiments, and semi-mechanistic PKPD modeling to separate inherited susceptibility changes from time-dependent adaptive resistance to ceftolozane-tazobactam. The study shows that AmpC G183D and AmpD H157Y mutations have distinct and strongly amplified effects when combined, providing a framework for interpreting resistance trajectories beyond MIC measurements.

• Sulfamonomethoxine: Mechanism to Stewardship

  2026-08-17

  Sulfamonomethoxine (SMM) is more than a veterinary sulfonamide antibiotic: it is a useful model for connecting DHPS inhibition, matrix effects, and environmental biotransformation. This article translates aerobic granular sludge findings into better assay design and more defensible stewardship decisions.

• Metronidazole: A Dual-Readout Research Strategy

  2026-08-16

  Metronidazole is more than a nitroimidazole antibiotic: it can connect anaerobic bacteria targeting with quantitative OAT3 transporter studies. This guide presents a dual-readout workflow for separating antimicrobial effects, transporter inhibition, and drug-drug interaction modulation.

• Cefotaxime Workflows for Resistance Research

  2026-08-15

  Cefotaxime provides a practical phenotype layer for studying beta-lactam resistance, plasmid transfer, and bacterial growth under selective pressure. This guide connects the compound to reproducible susceptibility assays, transmission workflows, and troubleshooting strategies informed by recent carbapenem-resistant Enterobacter cloacae research.

• PTEN mRNA Delivery: From Mechanism to Translation

  2026-08-14

  PTEN mRNA is moving from a molecular replacement concept toward a delivery-defined translational strategy. This article examines the biology of PTEN restoration, the role of Cap 1 and poly(A) architecture, and how EZ Cap™ Human PTEN mRNA can support reproducible cancer research and formulation development.

• Meropenem trihydrate for Resistance Phenotyping

  2026-08-14

  Meropenem trihydrate is a practical carbapenem antibiotic for linking growth inhibition with resistance biology, from MIC testing to LC-MS/MS metabolomics. This workflow emphasizes matched controls, short-term solution handling, and assay designs that distinguish baseline metabolic signatures from drug-induced responses.

685 records 1/46 page Next 12345 下5页 Last page